PRESS RELEASE: CytoGenix Announces Groundbreaking for New Facility; New Jobs

CytoGenix Announces Groundbreaking for New Facility; New Jobs

HOUSTON -- CytoGenix announced today it is breaking ground on its new 20,000 square foot facility which will house the Company offices, laboratory and DNA production plant. The new building will be located at 6030 North Course Drive in the Westchase district of Southwest Houston. The groundbreaking is scheduled for 10:00 AM. Mayor Bill White of Houston as well as representatives from the offices of Congressmen Al Green (9th District of Texas), John Culberson (7th District of Texas) and John Moss representing Texas State Senator Kyle Janek's office are expected to attend.

 

The land for the project is being purchased from GSL Welcome Group. Design Builder for the project is Kingham Dalton Wilson, Inc. (KDW) a provider of integrated commercial developments, specializing in Build-to-Suit facilities. The design for the building and research laboratory facilities was completed by Arcon Architects of League City, Texas.

"This facility will provide the Company the space needed to expand both our research and development and our DNA production. The additional capacity will enable more rapid progress in moving our own products to clinical trials as well as increasing our output of DNA products to our customers," stated Malcolm Skolnick, CytoGenix CEO.

Dr. Yin Chen, Chief Scientific Officer, comments, "This new facility will enable us to recruit additional highly qualified scientists and professionals needed in both our drug development and DNA production activities. The Company will move to expedite the certification process to achieve Good Manufacturing Practice (GMP) status necessary to manufacture clinical grade DNA."

Dr. Frederic Kendirgi, Senior Scientist overseeing the Company's DNA production platforms, notes, "The building of a custom designed Research and Production facility demonstrates our commitment to design and produce high quality DNA material under controlled environment with state of the art equipment and infrastructure. This expansion will secure CytoGenix' place in the current highly competitive DNA production market."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and single stranded DNA (ssDNA) expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside target cell. CytoGenix currently holds 13 granted patents and about 57 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.